Rein Therapeutics(RNTX)
$0.55-0.01 (-1.43%)
RNTX
Rein Therapeutics stock drug pipeline
$0.55
At close:-0.01 (-1.43%)
Want to see RNTX full AI Analyst Report?
Rein Therapeutics (RNTX) Drug Pipeline
1,220 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Dry powder inhaler, Lti-03 | Idiopathic Pulmonary Fibrosis (Ipf) | Phase II | Active Not Recruiting | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | Apr 28, 2025 | ― |
| Lti-03 | Idiopathic Pulmonary Fibrosis | Phase I | Completed | A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients | May 20, 2022 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Dry powder inhaler, Lti-03 | Phase II | Idiopathic Pulmonary Fibrosis (Ipf) | Active Not Recruiting | A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis | Apr 28, 2025 | ― |
| Lti-03 | Phase I | Idiopathic Pulmonary Fibrosis | Completed | A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients | May 20, 2022 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Rein Therapeutics, Inc (RNTX) have in its pipeline
Rein Therapeutics RNTX is currently developing the following drugs: Dry powder inhaler, Lti-03, Lti-03. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
